Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach

被引：0
|
作者：
Jung Won Chun
Sang Hyub Lee
Joo Seong Kim
Namyoung Park
Gunn Huh
In Rae Cho
Woo Hyun Paik
Ji Kon Ryu
Yong-Tae Kim
机构：
[1] Center for Liver and Pancreatobiliary Cancer,Department of Internal Medicine and Liver Research Institute
[2] Research Institute and Hospital,undefined
[3] National Cancer Center,undefined
[4] Seoul National University Hospital,undefined
[5] Seoul National University College of Medicine,undefined
来源：
BMC Cancer | / 21卷
关键词：
Pancreatic neoplasms; Folfirinox; Albumin-bound paclitaxel; Survival;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach
    Chun, Jung Won
    Lee, Sang Hyub
    Kim, Joo Seong
    Park, Namyoung
    Huh, Gunn
    Cho, In Rae
    Paik, Woo Hyun
    Ryu, Ji Kon
    Kim, Yong-Tae
    BMC CANCER, 2021, 21 (01)
  • [2] Comparison between FOLFIRINOX and Gemcitabine plus Nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach
    Chun, Jung Won
    Lee, Sang Hyub
    Kim, Joo Seong
    Park, Namyoung
    Huh, Gunn
    Cho, In Rae
    Paik, Woo Hyun
    Ryu, Ji Kon
    Kim, Yong-Tae
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 118 - 118
  • [3] Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
    Han, Sung Yong
    Kim, Dong Uk
    Seol, Young Mi
    Kim, Suk
    Lee, Nam Kyung
    Hong, Seung Baek
    Seo, Hyung-Il
    WORLD JOURNAL OF CLINICAL CASES, 2020, 8 (17) : 3718 - 3729
  • [4] Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
    Sung Yong Han
    Dong Uk Kim
    Young Mi Seol
    Suk Kim
    Nam Kyung Lee
    Seung Baek Hong
    Hyung-Il Seo
    World Journal of Clinical Cases, 2020, (17) : 3718 - 3729
  • [5] Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancreatic Cancer Propensity Score Matching
    Mie, Takafumi
    Sasaki, Takashi
    Takeda, Tsuyoshi
    Fukuda, Koshiro
    Furukawa, Takaaki
    Yamada, Yuto
    Kasuga, Akiyoshi
    Matsuyama, Masato
    Ozaka, Masato
    Sasahira, Naoki
    PANCREAS, 2021, 50 (04) : 595 - 601
  • [6] FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study
    Servetto, Alberto
    Santaniello, Antonio
    Napolitano, Fabiana
    Foschini, Francesca
    Marciano, Roberta
    Cascetta, Priscilla
    Amato, Anna Rita
    Augurio, Maria Rosaria
    Maresca, Lucia
    De Placido, Pietro
    De Placido, Sabino
    Formisano, Luigi
    Bianco, Roberto
    FUTURE ONCOLOGY, 2022, 18 (21) : 2643 - 2654
  • [7] Sequential treatment with Nab-paclitaxel plus Gemcitabine and Folfirinox in metastatic pancreatic adenocarcinoma: GABRINOX phase II results.
    Assenat, Eric
    De La Fouchardiere, Christelle
    Mollevi, Caroline
    Samalin, Emmanuelle
    Portales, Fabienne
    Desseigne, Francoise
    Carenco, Christophe
    Dupuy, Marie
    Lopez-Martinez, Ernesto
    Fiess, Catherine
    Mazard, Thibault
    Ychou, Marc
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer Using Korean Pancreatic Cancer (K-PaC) Registry
    Lee, Jong-chan
    Woo, Sang Myung
    Shin, Dong Woo
    Kim, Jinkook
    Yang, Se Yeol
    Kim, Min Jae
    Kim, Jin Won
    Kim, Ji-Won
    Lee, Woo Jin
    Cha, Hyo Soung
    Park, Philiip
    Kim, Jaihwan
    Hwang, Jin-Hyeok
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2020, 43 (09): : 654 - 659
  • [9] Nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreatic cancer: our experience
    Mare, M.
    Munao, S.
    Germana, S.
    Colarossi, C.
    Sciacca, D.
    Giuffrida, D.
    Giannone, G.
    ANNALS OF ONCOLOGY, 2017, 28
  • [10] A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study
    Taiga Otsuka
    Tsuyoshi Shirakawa
    Mototsugu Shimokawa
    Futa Koga
    Yasunori Kawaguchi
    Yujiro Ueda
    Junichi Nakazawa
    Azusa Komori
    Satoshi Otsu
    Shiho Arima
    Masaru Fukahori
    Yoshinobu Okabe
    Akitaka Makiyama
    Hiroki Taguchi
    Takuya Honda
    Taro Shibuki
    Kenta Nio
    Yasushi Ide
    Toshihiko Mizuta
    Kenji Mitsugi
    Norio Ureshino
    International Journal of Clinical Oncology, 2021, 26 : 941 - 950
12345